Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: A placebo-controlled trial

Obesity Research

Volumn 8, Issue 6, 2000, Pages 431-437

  Wadden, Thomas A ^a   Berkowitz, Robert I ^a   Womble, Leslie G ^a   Sarwer, David B ^a   Arnold, Marjorie E ^a   Steinberg, Carrie M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Obesity; Orlistat; Sibutramine; Weight loss; Women

Indexed keywords

ANOREXIGENIC AGENT; ANTIOBESITY AGENT; CYCLOBUTANE DERIVATIVE; LACTONE; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECT; FEMALE; HUMAN; LIFESTYLE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OBESITY; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; TIME;

ADULT; ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; BODY MASS INDEX; BODY WEIGHT; COMBINED MODALITY THERAPY; CYCLOBUTANES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LACTONES; LIFE STYLE; MIDDLE AGED; OBESITY; PILOT PROJECTS; TIME FACTORS;

EID: 0034264256     PISSN: 10717323     EISSN: None     Source Type: Journal    
DOI: 10.1038/oby.2000.53     Document Type: Article

References (22)

1. Knoll Pharmaceutical Co. Mendia (sibutramine hydrochloride monohydrate). Prescribing information. In: Physician's Desk Reference. Montvale, NJ: Drug Information Services Group; 2000, pp. 1509-13.
2. Roche Laboratories. Xenical (orlistat). Prescribing information. In: Physician's Desk Reference. Montvale, NJ: Drug Information Services Group; 2000, pp. 2693-6.
3. Lean MEJ. Sibutramine: a review of clinical efficacy. Int J Obes. 1997;21:30S-6S.
4. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999;281:235-42.
5. Heymsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Int Med. 2000;160:1321-6.
6. Sjöström L, Rissanen A, Anderson T, et al. Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 1998;352:167-73.
7. Foster GD, Wadden TA, Vogt RA. What is a reasonable weight loss?: patients' expectations and evaluations of obesity treatment outcomes. J Consult Clin Psychol. 1997;65:79-85.
8. Bray GA, Greenway FL. Current and potential drugs for treatment of obesity. Endocr Rev. 2000;20:805-75.
9. Atkinson RL, Blank RC, Schumacher D, Dhurandhar NV, Ritch DL. Long-term drug treatment of obesity in a private practice setting. Obes Res. 1997;5:578-86.
10. Weintraub M, Sundaresan PR, Madan M, et al. Long-term weight control study I (weeks 0 to 34): the enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin Pharmacol Ther. 1992;51:586-94.
11. Wadden TA, Berkowitz RI, Sarwer DB, Prus-Wisniewski R, Steinberg CM. Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial. Arch int Med., in press.
12. Wadden TA, Sarwer DB, Berkowitz RI. Behavioral treatment of the overweight patient. Bailliere's Clin Endocrin Metab. 1999;13:93-107.
13. Brownell KD. The Learn Program for Weight Management 2000. Dallas, TX: American Health Publishing Co. 2000, pp. 209-10.
14. Ravussin E, Swinburn BA. Effect of caloric restriction and weight loss on energy expenditure. In: Wadden TA, VanItallie TB, ed. Treatment of the Seriously Obese Patient. New York: Guilford Press; 1992, pp. 163-89.
15. Campfield LA, Smith FJ, Burn P. The OB protein (leptin) pathway: a link between adipose tissue mass and central neural networks. J Metab Res. 1996;28:619-32.
16. Stunkard AJ. Mini review: anorectic agents lower a body weight set point. Life Sci. 1982;30:2043-55.
17. Andersen T, Astrup A, Quaade F. Dexfenfluramine as adjuvant to a low-calorie formula diet in the treatment of obesity: a randomized clinical trial. Int J Obes. 1992;16:35-40.
18. Wadden TA, Foster GD, Letizia KA. One-year behavioral treatment of obesity: comparison of moderate and severe caloric restriction and the effects of maintenance therapy. J Consult Clin Psychol. 1994;62:165-71.
19. Andersen T, Astrup A, Quaade F. Dexfenfluramine as adjuvant to a low-calorie formula diet in the treatment of obesity: a randomized clinical trial. Int J Obes. 1992;16:35-40.
20. Hill JO, Hauptman J, Anderson JW, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-year study. Am J Clin Nutr. 1999;69:1108-16.
21. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337:581-8.
22. Brownell KD, Stunkard AJ. The double-blind in danger: untoward consequences of informed consent. Am J Psychiatry. 1982;139:1487-9.